Last reviewed · How we verify
A Phase I/IIa, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerance, and Preliminary Activity of Intravenous High-Dose Fluphenazine HCI in Patients With Advanced Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as fluphenazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of fluphenazine and to see how well it works in treating patients with refractory advanced multiple myeloma.
Details
| Lead sponsor | Immune Control |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | COMPLETED |
| Enrolment | 30 |
| Start date | 2006-01 |
Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
Interventions
- fluphenazine hydrochloride
Primary outcomes
- Safety
- Efficacy
Countries
United States